Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Actuarialon Feb 25, 2021 11:36am
136 Views
Post# 32658177

RE:RE:RE:Last Chance

RE:RE:RE:Last ChanceATE/AH amalgamation should not be viewed as a strong positive nor negative event. AH was there ever since the birth of ATE. AH will take a cut either in a format of percentage of royalty, or, in a format of shareholder - it is the same unless ATE overpay AH to convert royalty into shares. The only way to hurt current shareholders is another PP, which is remote or even would not need in future imo. I bet the current sale of ATE were from PP participants. While the last PP is at $6 per share, I suspect these PP participants also enjoyed the PP before the last PP at $4 per share. And therefore, they can sell their common shares at much lower price than $6 and hold warrants for free. Two PP within eight months hurt retail investors hard. However, that is the price we have to pay. ATE will fly, and soon. The sky is the limit. GLTA longs! 

Goaweigh wrote: Yes, this is now the only issue outstanding that could negatively impact the price in the near term however I suspect the Underwriters of the $ 40 Mill were given some range of the most likely outcomes before writing that cheque. The issue must have been addressed and addressed. 



Doublett wrote: I would hold out for the amaligimation dilution before thinking about loading




<< Previous
Bullboard Posts
Next >>